ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
January 13, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- First-in-class orally active...
ObsEva Announces Results of the IMPLANT Phase 2 Trial of OBE001 (nolasiban) for the Improvement of Pregnancy and Live Birth Rates Following IVF/ICSI
October 24, 2016 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Trial shows meaningful increase in...
ObsEva Announces Plans to Conduct Initial Public Offering in the United States
October 17, 2016 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
GENEVA, SWITZERLAND, 17 October, 2016 -...
ObsEva Randomizes First Patient in Phase 2b EDELWEISS Study of OBE2109 for the Treatment of Endometriosis
October 12, 2016 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- Clinical trial to assess safety and...
ObsEva to Present at 2016 Wedbush Pacgrow Healthcare Conference
August 10, 2016 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
PRESS RELEASE ObsEva to Present at...
ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2alpha Antagonist, for the Treatment of Preterm Labor
July 28, 2016 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
PRESS RELEASE ObsEva Initiates Phase...
ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis
July 06, 2016 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
PRESS RELEASE ObsEva Receives Clearance...
ObsEva to Webcast Presentation at 15th Annual Needham Healthcare Conference
April 05, 2016 08:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 05 April, 2016 -...
ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel
March 24, 2016 08:08 ET
|
ObsEva SA
GENEVA, March 24, 2016 (GLOBE NEWSWIRE) -- ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced the appointment of Frank...
ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel
March 24, 2016 08:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 24 March 2016 - ObsEva, a...